3.5-Dimethoxy-benzoyl-isothiocyanat | 94096-16-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3.5-Dimethoxy-benzoyl-isothiocyanat
• 英文别名: 3,5-Dimethoxy-1-benzenecarbonyl isothiocyanate；3,5-dimethoxybenzoyl isothiocyanate
• CAS: 94096-16-9
• 化学式: C₁₀H₉NO₃S
• mdl: MFCD13680314
• 分子量: 223.252
• InChiKey: LWRGLYIRRRLOTO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  80
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3.5-Dimethoxy-benzoyl-isothiocyanat 、 N-(3-氨基苯基)苯甲酰胺 以 丙酮 为溶剂， 反应 1.0h， 生成 3,5-dimethoxy-N-(3-phenylamidophenylcarbamothioyl)benzamide
  参考文献：
  名称：

  Acylthiourea, Acylurea, and Acylguanidine Derivatives with Potent Hedgehog Inhibiting Activity

  摘要：

  The Smoothened (Smo) receptor is the major transducer of the Hedgehog (Hh) signaling pathway. On the basis of the structure of the acylthiourea Smo antagonist (MRT-10), a number of different series of analogous compounds were prepared by ligand-based structural optimization. The acylthioureas, originally identified as actives, were converted into the corresponding acylureas or acylguanidines. In each series, similar structural trends delivered potent compounds with IC50 values in the nanomolar range with respect to the inhibition of the Hh signaling pathway in various cell-based assays and of BODIPY-cyclopamine binding to human Smo. The similarity of their biological activities, in spite of discrete structural differences, may reveal the existence of hydrogen-bonding interactions between the ligands and the receptor pocket. Biological potency of compounds 61, 72, and 86 (MRT-83) were comparable to those of the clinical candidate GDC-0449. These findings suggest that these original molecules will help delineate Smo and Hh functions and can be developed as potential anticancer agents.

  DOI：

  10.1021/jm2013369
• 作为产物：
  描述：

  3,5-二甲氧基苯甲酸 在 氯化亚砜 、 N,N-二甲基甲酰胺 作用下， 以 丙酮 为溶剂， 生成 3.5-Dimethoxy-benzoyl-isothiocyanat
  参考文献：
  名称：

  1-Aroyl-3-[3-chloro-2-methylphenyl] 硫脲杂化物作为有效脲酶抑制剂的分析：合成、生化评价和计算方法

  摘要：

  脲酶是一种酰胺水解酶，可导致人体内的致命疾病，例如导管结痂、脑病、消化性溃疡、肝昏迷、肾结石形成等。近年来，科学家们为寻找高效的脲酶抑制剂付出了相当大的努力。在药物化学中，硫脲骨架起着至关重要的作用。因此，目前的工作集中在新型脲酶抑制剂的开发和发现上，并报道了一组具有脂肪族和芳香族侧链4a - j的 1-aroyl-3-[3-chloro-2-methylphenyl] 硫脲杂化物的合成。通过不同的分析技术对化合物进行表征，包括 FT-IR、1 H-NMR 和1313C-NMR，并评估了对杰克豆脲酶 (JBU) 的体外酶抑制活性，发现它们是有效的抗脲酶抑制剂，抑制活性 IC 50的范围为 0.0019 ± 0.0011 至 0.0532 ± 0.9951 μM，与标准硫脲相比 (IC 50 = 4.7455 ± 0.0545 μM)。其他研究包括密度泛函理论 (DFT)、抗氧化自由基清除测定、物理化学特性

  DOI：

  10.3390/ijms231911646

文献信息

• Design, Synthesis, and Insecticidal Activity of Novel Doramectin Derivatives Containing Acylurea and Acylthiourea Based on Hydrogen Bonding
  作者：Qi Zhang、Yao Cheng、Cheng Zheng、Ping Bai、Jian Yang、Xiaoxia Lu

  DOI：10.1021/acs.jafc.0c00230

  日期：2020.5.27

  investigation on the insecticidal activities of several doramectin derivatives preliminarily revealed that the presence of hydrogen bonds at the C4″ position of the molecule with target protein γ-aminobutyric acid (GABA) receptor was crucial for retaining high insecticidal activity. As a continuation of our research work on the development of new insecticides, two series of novel acylurea and acylthiourea

  我们最近对几种多拉菌素衍生物的杀虫活性的研究初步表明，在具有目标蛋白γ-氨基丁酸（GABA）受体的分子的C4''位置存在氢键对于保持高杀虫活性至关重要。作为我们对新型杀虫剂开发的研究工作的继续，设计并合成了两个系列的新型酰基脲和酰基硫脲多拉菌素衍生物。生物测定结果表明，在我们的实验室中，新合成的化合物（5o，5t和6t）对小菜蛾，东方粘虫和玉米bore的杀虫活性高于对照化合物doramectin，市售阿维菌素，敌百虫和铅化合物3g。特别，化合物5t被确定为最有前景的小菜蛾杀虫剂，在低浓度12.50 mg / L时最终死亡率为80.00％，其效力比母体多拉菌素高约7.75倍（LC50值为48.1547 mg / L ），效力比市售阿维菌素（LC50值为40.5507 mg / L）高6.52倍，效力比化合物3g（LC50值为24.7742 mg / L）高3.98倍。此外，分子对接模拟显示化合物5t（2
• Synthesis, molecular docking studies, and in vitro screening of sulfanilamide-thiourea hybrids as antimicrobial and urease inhibitors
  作者：Aamer Saeed、Sumera Zaib、Arshid Pervez、Amara Mumtaz、Mohammad Shahid、Jamshed Iqbal

  DOI：10.1007/s00044-012-0376-4

  日期：2013.8

  A series of novel hybrid molecules containing sulfanilamide and thiourea templates was designed and synthesized. These compounds were screened for antimicrobial and urease inhibitory activities. Some of the compounds revealed promising antibacterial and antifungal activities. Fascinatingly, the majority of the compounds exhibited potential urease inhibitory activities with IC50 ranging from 0.20 to

  设计并合成了一系列含有磺胺和硫脲模板的新型杂化分子。筛选了这些化合物的抗微生物和脲酶抑制活性。一些化合物显示出令人鼓舞的抗菌和抗真菌活性。令人着迷的是，大多数化合物都表现出潜在的脲酶抑制活性，IC 50为0.20至7.50μM。化合物2b被确定为最有效的脲酶抑制剂（IC 50为0.20μM），且效力比标准抑制剂硫脲高100倍。化合物的分子对接研究是在Jack bean和幽门螺杆菌脲酶的3D晶体结构上进行的。
• Quinoline and quinazoline derivatives and drugs containing the same
  申请人：——

  公开号：US20040132727A1

  公开（公告）日：2004-07-08

  There are provided compounds which can be used in the treatment of diseases mediated by the autophosphorylation of a PDGF receptor, specifically, compounds which can inhibit neointima formation hypertrophy. The compounds are those represented by formula (I) or pharmacologically acceptable salts or solvates thereof: 1 wherein R 1 and R 2 represent hydrogen, alkyl or the like; R 3 , R 4 , R 5 and R 6 represent hydrogen, halogen, alkyl, alkoxy or the like; R 11 and R 12 represent hydrogen, alkyl, alkylcarbonyl or the like; and A represents any one of formulae (i) to (x), provided that compounds wherein R 3 , R 4 , R 5 and R 6 represent hydrogen and A represents group (v) wherein u is 0 (zero) and R 19 represents phenyl optionally substituted by halogen, alkyl, or alkoxy are excluded.

  提供了一些化合物，可用于治疗由PDGF受体自磷酸化介导的疾病，特别是可抑制新内膜形成肥大的化合物。这些化合物由式（I）或其药理学上可接受的盐或溶剂表示：1其中R1和R2表示氢，烷基或类似物；R3、R4、R5和R6表示氢，卤素，烷基，烷氧基或类似物；R11和R12表示氢，烷基，烷基羰基或类似物；而A表示公式（i）到（x）中的任意一个，但其中R3、R4、R5和R6表示氢，A表示组（v）其中u为0（零）且R19表示苯基，可选地被卤素，烷基或烷氧基取代的化合物被排除。
• QUINOLINE AND QUINAZOLINE DERIVATIVES AND DRUGS CONTAINING THE SAME
  申请人：KIRIN BEER KABUSHIKI KAISHA

  公开号：EP1243582A1

  公开（公告）日：2002-09-25

  There are provided compounds which can be used in the treatment of diseases mediated by the autophosphorylation of a PDGF receptor, specifically, compounds which can inhibit neointima formation hypertrophy. The compounds are those represented by formula (I) or pharmacologically acceptable salts or solvates thereof: wherein R1 and R2 represent hydrogen, alkyl or the like; R3, R4, R5, and R6 represent hydrogen, halogen, alkyl, alkoxy or the like; R11 and R12 represent hydrogen, alkyl, alkylcarbonyl or the like; and A represents any one of formulae (i) to (x), provided that compounds wherein R3, R4, R5 and R6 represent hydrogen and A represents group (v) wherein u is 0 (zero) and R19 represents phenyl optionally substituted by halogen, alkyl, or alkoxy are excluded.

  提供了可用于治疗由 PDGF 受体自身磷酸化介导的疾病的化合物，特别是可抑制新内膜形成肥厚的化合物。这些化合物是式 (I) 所代表的化合物或其药理学上可接受的盐或溶液： 其中 R1 和 R2 代表氢、烷基或类似物；R3、R4、R5 和 R6 代表氢、卤素、烷基、烷氧基或类似物；R11 和 R12 代表氢、烷基、烷基羰基或类似物；A 代表式(i)至(x)中的任意一种，但不包括 R3、R4、R5 和 R6 代表氢且 A 代表基团(v)（其中 u 为 0（零）且 R19 代表任选被卤素、烷基或烷氧基取代的苯基）的化合物。
• SYNTHESIS OF BENZOYL-<i>N</i>-PHENYLTHIOUREAS UNDER MICROWAVE IRRADIATION AND PHASE TRANSFER CATALYSIS CONDITIONS
  作者：Lin Bai、Shengying Li、Jin-Xian Wang、Mingkai Chen

  DOI：10.1081/scc-120001519

  日期：2002.1.1

  A simple, rapid and efficient method for the synthesis of benzoyl-N-phenylthioureas under microwave irradiation is reported. The effect of microwave irradiation power, times and phase transfer catalyst on the reaction is investigated.